$XOMA Corp generated 3 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on 2025-07-21. @jacobplieth (@jacobplieth) was the most active voice discussing the ticker, with 4 mentions, while @ssi_invest (Special Situation Investments) contributed 1 mention. The most recent discussion occurred on 2026-04-28, focusing on biotech sector dynamics and corporate developments.

The latest substantive mention centered on XOMA's acquisition by Ligand Pharmaceuticals ($LGND) at $39 per share in cash plus a contingent value right tied to TREMFYA litigation proceedings against Johnson & Johnson ($JNJ). The acquisition structure included a breach of contract claim component, with the deal expected to close in Q3'26. Earlier mentions by @jacobplieth referenced XOMA in the context of broader biotech sector trends, including discussion of R&D selectivity and royalty aggregation strategies among peer companies.